NCT05041907.

Study name	Finding treatments for COVID‐19: a trial of antiviral pharmacodynamics in early symptomatic COVID‐19 (PLATCOV) (PLATCOV)
Methods	Trial design: open‐label RCT with 5 parallel arms, only 2 arms relevant; the third arm investigates favipavir, the fourth arm arms investigates remdesivir, the fifth arm investigates monoclonal antibodies Type of record: trial register entry Sample size: 750 Setting:outpatient Country: Thailand Language: English Number of centres: NR Study purpose (treatment, prevention): treatment Trial registration number: NCT05041907 Date of registration: 13 September 2021
Participants	Inclusion criteria Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study Previously healthy adults, male or female, aged 18‐50 years at time of consent with early symptomatic COVID‐19 SARS‐CoV‐2 positive by lateral flow antigen test Symptoms of COVID‐19 (including fever, or history of fever) < 4 days (96 hours) Oxygen saturation ≥ 96% measured by pulse oximetry at time of screening Able to walk unaided and unimpeded in activities of daily living Agrees and is able to adhere to all study procedures, including availability and contact information for follow‐up visits Exclusion criteria Taking any concomitant medications or drugs Presence of any chronic illness/ condition requiring long‐term treatment, or other significant comorbidity Laboratory abnormalities discovered at screening For females: pregnancy, actively trying to become pregnant, or lactation Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics Currently participating in another COVID‐19 therapeutic or vaccine trial Evidence of pneumonie (although imaging is not required)
Interventions	Details of intervention of relevant arms Type and dose: ivermectin 0.6 mg/kg, once daily for 7 days Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care (supportive care only) administered in both study arms
Outcomes	Primary study outcome Rate of viral clearance for repurposed drugs within 7 days Rate of viral clearance of positive control (monoclonal antibodies) over time relative to the negative control within 7 days Rate of viral clearance for small novel molecule drugs within 7 days Relevant review outcomes planned Rates of hospitalization by treatment arm within 28 days Viral cleareance Additional study outcomes Viral kinetic levels in early COVID‐19 disease within 7 days Number of antiviral treatment arms that show a positive signal (> 90% probability of > 5% acceleration in viral clearance) within 7 days Rates of viral clearance by treatment arm, as compared against REGN‐COV2 (monoclonal antibody cocktail) within 7 days Rates of hospitalization by treatment arm within 28 days
Starting date	30 September 2021
Contact information	Nicholas White Professor of Tropical Medicine at Mahidol University Phutthamonthon Thailand
Notes	Recruitment status: recruiting Prospective completion date: August 2023 Planned completion date more than 6 months ago: no Date last update posted: 12 January 2022 Sponsor/funding: University of Oxford